Interestingly, in diffuse large B-cell lymphoma (DLBCL), approximately 20% of patients bear activating EZH2 mutations (77), suggesting that PRC2 may have contrasting context-dependent roles in oncogenesis. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.